Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET XR versus ROSIGLITAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET XR versus ROSIGLITAZONE.
ACTOPLUS MET XR vs ROSIGLITAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTOPLUS MET XR combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating PPAR-γ, and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Selective agonist at peroxisome proliferator-activated receptor gamma (PPARγ), enhancing insulin sensitivity by increasing glucose uptake and storage, reducing hepatic glucose production, and improving lipid metabolism.
Initial dose: 15 mg pioglitazone/500 mg metformin hydrochloride extended-release orally once daily with evening meal. Titrate based on glycemic response, maximum dose 45 mg pioglitazone/2000 mg metformin hydrochloride extended-release per day.
4-8 mg orally once daily or divided twice daily; maximum 8 mg/day.
None Documented
None Documented
Clinical Note
moderateRosiglitazone + Gatifloxacin
"Rosiglitazone may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateRosiglitazone + Rosoxacin
"Rosiglitazone may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateRosiglitazone + Levofloxacin
"Rosiglitazone may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateRosiglitazone + Trovafloxacin
"Rosiglitazone may increase the hypoglycemic activities of Trovafloxacin."
Pioglitazone: terminal half-life 3-7 hours (parent), 16-24 hours (active metabolites); clinical effect sustained due to metabolites. Metformin: terminal half-life 6.2 hours (plasma), elimination prolonged in renal impairment (creatinine clearance <60 mL/min).
Terminal elimination half-life is 3-4 hours. Clinically, this short half-life allows twice-daily dosing; steady-state is achieved within 2 days.
Pioglitazone: predominantly hepatic metabolism, 15-30% excreted in urine as metabolites, ~20% in feces. Metformin: 90% renal excretion unchanged via glomerular filtration and tubular secretion.
Primarily hepatic metabolism via CYP2C8; negligible renal excretion. Approximately 64% of dose excreted in urine (as metabolites) and 23% in feces over 96 hours. Less than 0.2% excreted unchanged in urine.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione